Hormonal
GLP-1 receptor agonists (GLP-1RAs) significantly reduce systolic blood pressure, total stroke risk, and cardiovascular mortality in patients with type 2 diabetes or obesity.
If you have Type 2 Diabetes or Obesity and are at risk for heart disease or stroke, GLP-1 medications (like Semaglutide or Liraglutide) are strongly supported by evidence to lower your risk of heart attack, stroke, and cardiovascular death. Discuss these options with your doctor, especially if you have existing cardiovascular conditions.
For cardiovascular disease, most studies found GLP-1RAs reduced systolic blood pressure, total stroke, and myocardial mortality.
Why this rating
Supported by multiple large-scale meta-analyses and randomized controlled trials (RCTs) involving tens of thousands of patients.
Source
Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
Kathryn Haran et al. · Psoriasis Targets and Therapy · 2024
DOI 10.2147/ptt.s485061
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →